The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Novel pharmacological targets for the treatment of Parkinson's disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807
Self-citationMolecular Pathways of Neurodegeneration in Parkinson's Disease
Dawson, T. M., & Dawson, V. L. (2003) · Science · doi:10.1126/science.1087753 · Cited by 1,663
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications
Mansour, A., Fox, C. A., Akil, H., & Watson, S. J. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93946-u · Cited by 1,292
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251
Rivastigmine for Dementia Associated with Parkinson's Disease
Emre, M., Aarsland, D., Albanese, A., Byrne, E. J., Deuschl, G., De Deyn, P. P., Durif, F., Kulisevsky, J., van Laar, T., Lees, A., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041470 · Cited by 1,223
Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's Disease
(1993) · New England Journal of Medicine · doi:10.1056/nejm199301213280305 · Cited by 1,221
Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine
Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., Seeman, P., & Wong, D. T. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(94)00129-n · Cited by 1,062
Effects of Coenzyme Q10 in Early Parkinson Disease: Evidence of Slowing of the Functional Decline
Shults, C. W. (2002) · Archives of Neurology · doi:10.1001/archneur.59.10.1541 · Cited by 984
Lang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 983
Parsons, C. G., Danysz, W., & Quack, G. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00019-2 · Cited by 878
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study
Whone, A. L., Watts, R. L., Stoessl, A. J., Davis, M., Reske, S., Nahmias, C., Lang, A. E., Rascol, O., Ribeiro, M. J., Remy, P., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10609 · Cited by 829
Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD
Nutt, J. G., Burchiel, K. J., Comella, C. L., Jankovic, J., Lang, A. E., Laws, E. R., Lozano, A. M., Penn, R. D., Simpson, R. K., Stacy, M., et al. (2003) · Neurology · doi:10.1212/wnl.60.1.69 · Cited by 824
Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia
Picconi, B., Centonze, D., Håkansson, K., Bernardi, G., Greengard, P., Fisone, G., Cenci, M. A., & Calabresi, P. (2003) · Nature Neuroscience · doi:10.1038/nn1040 · Cited by 821
Parkinson Study Group (2002) · JAMA · doi:10.1001/jama.287.13.1653 · Cited by 711
Fink, J. S., Weaver, D. R., Rivkees, S. A., Peterfreund, R. A., Pollack, A. E., Adler, E. M., & Reppert, S. M. (1992) · Molecular Brain Research · doi:10.1016/0169-328x(92)90173-9 · Cited by 650
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 634
Self-citationNeuroprotection by Caffeine and A2AAdenosine Receptor Inactivation in a Model of Parkinson's Disease
Chen, J.-F., Xu, K., Petzer, J. P., Staal, R., Xu, Y.-H., Beilstein, M., Sonsalla, P. K., Castagnoli, K., Castagnoli, N., & Schwarzschild, M. A. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-10-j0001.2001 · Cited by 606
Self-citation(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
Pathophysiology of levodopa-induced dyskinesia: Potential for new therapies
Bezard, E., Brotchie, J. M., & Gross, C. E. (2001) · Nature Reviews Neuroscience · doi:10.1038/35086062 · Cited by 503
Self-citationA Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease
(2004) · Archives of Neurology · doi:10.1001/archneur.61.4.561 · Cited by 485
Le Novere, N., Zoli, M., & Changeux, J. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01206.x · Cited by 385
Does levodopa slow or hasten the rate of progression of Parkinson’s disease?
Fahn, S., & and the Parkinson Study Group (2005) · Journal of Neurology · doi:10.1007/s00415-005-4008-5 · Cited by 347
Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough
Lang, A. E., & Obeso, J. A. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00740-9 · Cited by 345
Self-citationDonepezil for cognitive impairment in Parkinson's disease: a randomised controlled study
Aarsland, D. (2002) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.72.6.708 · Cited by 341
Adenosine A 2A receptor antagonist treatment of Parkinson’s disease
Bara-Jimenez, W., Sherzai, A., Dimitrova, T., Favit, A., Bibbiani, F., Gillespie, M., Morris, M. J., Mouradian, M. M., & Chase, T. N. (2003) · Neurology · doi:10.1212/01.wnl.0000073136.00548.d4 · Cited by 327
Smoking, nicotine and Parkinson's disease
Quik, M. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.06.008 · Cited by 324
De Deurwaerdère, P., Navailles, S., Berg, K. A., Clarke, W. P., & Spampinato, U. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.0112-04.2004 · Cited by 306
Self-citationRandomized trial of the adenosine A 2A receptor antagonist istradefylline in advanced PD
Hauser, R. A., Hubble, J. P., Truong, D. D., & the Istradefylline US-001 Study Group (2003) · Neurology · doi:10.1212/01.wnl.0000081227.84197.0b · Cited by 300
Neuroprotection in Parkinson Disease: Mysteries, Myths, and Misconceptions
Schapira, A. H. V., & Olanow, C. W. (2004) · JAMA · doi:10.1001/jama.291.3.358 · Cited by 288
Self-citationKatzenschlager, R., Hughes, A., Evans, A., Manson, A. J., Hoffman, M., Swinn, L., Watt, H., Bhatia, K., Quinn, N., & Lees, A. J. (2005) · Movement Disorders · doi:10.1002/mds.20276 · Cited by 286
Grondin, R., Zhang, Z., Yi, A., Cass, W. A., Maswood, N., Andersen, A. H., Elsberry, D. D., Klein, M. C., Gerhardt, G. A., & Gash, D. M. (2002) · Brain · doi:10.1093/brain/awf234 · Cited by 283
Rescue of dying neurons: A new action for deprenyl in MPTP parkinsonism
Tatton, W. G., & Greenwood, C. E. (1991) · Journal of Neuroscience Research · doi:10.1002/jnr.490300410 · Cited by 272
Anticholinergics for symptomatic management of Parkinson´s disease
Katzenschlager, R., Sampaio, C., Costa, J., & Lees, A. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003735 · Cited by 259
Etiology of Parkinson’s disease
Schapira, A. H. V. (2006) · Neurology · doi:10.1212/wnl.66.10_suppl_4.s10 · Cited by 250
Self-citationAntiparkinsonian effect of a new selective adenosine A2Areceptor antagonist in MPTP-treated monkeys
Grondin, R., Bédard, P. J., Tahar, A. H., Grégoire, L., Mori, A., & Kase, H. (1999) · Neurology · doi:10.1212/wnl.52.8.1673 · Cited by 249
Fuxe, K., Agnati, L. F., Jacobsen, K., Hillion, J., Canals, M., Torvinen, M., Tinner-Staines, B., Staines, W., Rosin, D., Terasmaa, A., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000095206.44418.5c · Cited by 248
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
Xu, K., Bastia, E., & Schwarzschild, M. (2005) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.007 · Cited by 244
Self-citationSerotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models
Bibbiani, F., Oh, J. D., & Chase, T. N. (2001) · Neurology · doi:10.1212/wnl.57.10.1829 · Cited by 241
Marino, M. J., Williams, D. L., O'Brien, J. A., Valenti, O., McDonald, T. P., Clements, M. K., Wang, R., DiLella, A. G., Hess, J. F., Kinney, G. G., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835724100 · Cited by 240
The ‘magic’ of -dopa: why is it the gold standard Parkinson's disease therapy?
MERCURI, N., & BERNARDI, G. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.05.002 · Cited by 232
Wadia, J. S., Chalmers-Redman, R. M. E., Ju, W. J. H., Carlile, G. W., Phillips, J. L., Fraser, A. D., & Tatton, W. G. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-03-00932.1998 · Cited by 230
Randomized placebo‐controlled trial of donepezil in cognitive impairment in Parkinson's disease
Leroi, I., Brandt, J., Reich, S. G., Lyketsos, C. G., Grill, S., Thompson, R., & Marsh, L. (2004) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.993 · Cited by 226
Clozapine improves dyskinesias in Parkinson disease: A double-blind, placebo-controlled study
Durif, F., Debilly, B., Galitzky, M., Morand, D., Viallet, F., Borg, M., Thobois, S., Broussolle, E., & Rascol, O. (2004) · Neurology · doi:10.1212/01.wnl.0000110317.52453.6c · Cited by 224
Continuous dopamine-receptor stimulation in early Parkinson's disease
Olanow, C. W., Schapira, A. H. V., & Rascol, O. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00030-6 · Cited by 208
Self-citationBibbiani, F., Oh, J. D., Petzer, J. P., Castagnoli, N., Chen, J.-F., Schwarzschild, M. A., & Chase, T. N. (2003) · Experimental Neurology · doi:10.1016/s0014-4886(03)00250-4 · Cited by 204
Self-citationSmoking and Parkinson's disease: Systematic review of prospective studies
Allam, M. F., Campbell, M. J., Hofman, A., Del Castillo, A. S., & Fernández‐Crehuet Navajas, R. (2004) · Movement Disorders · doi:10.1002/mds.20029 · Cited by 192
Opioid Peptide Processing and Receptor Selectivity
Hollt, V (1986) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.26.040186.000423 · Cited by 190
McGreevy, P., Grassi, T. D., & Harman, A. M. (2004) · Brain, Behavior and Evolution · doi:10.1159/000073756 · Cited by 185
Pharmacological actions of the atypical antipsychotic drug clozapine: A review
Ashby, C. R., & Wang, R. Y. (1996) · Synapse · doi:10.1002/(sici)1098-2396(199612)24:4<349::aid-syn5>3.0.co;2-d · Cited by 184
Brooks, D. J. (2003) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.74.8.1071 · Cited by 182
Buspirone in Levodopa-Induced Dyskinesias
Bonifati, V., Fabrizio, E., Cipriani, R., Vanacore, N., & Meco, G. (1994) · Clinical Neuropharmacology · doi:10.1097/00002826-199402000-00008 · Cited by 181
Effect of Nondopaminergic Drugs on L-DOPA-Induced Dyskinesias in MPTP-Treated Monkeys
Gomez-Mancilla, B., & Bedard, P. J. (1993) · Clinical Neuropharmacology · doi:10.1097/00002826-199310000-00004 · Cited by 181
Newman-Tancredi, A., Cussac, D., Audinot, V., Nicolas, J.-P., De Ceuninck, F., Boutin, J.-A., & Millan, M. J. (2002) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.039875 · Cited by 179
Timing of treatment initiation in Parkinson's disease: A need for reappraisal?
Schapira, A. H. V., & Obeso, J. (2006) · Annals of Neurology · doi:10.1002/ana.20789 · Cited by 177
Self-citationOlanow, C. W., Damier, P., Goetz, C. G., Mueller, T., Nutt, J., Rascol, O., Serbanescu, A., Deckers, F., & Russ, H. (2004) · Clinical Neuropharmacology · doi:10.1097/00002826-200403000-00003 · Cited by 175
De Deurwaerdère, P., & Spampinato, U. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731033.x · Cited by 164
Self-citationIstradefylline, a novel adenosine A2Areceptor antagonist, for the treatment of Parkinson’s disease
Jenner, P. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.6.729 · Cited by 160
Self-citationEffects of serotonin 5‐HT1A agonist in advanced Parkinson's disease
Bara‐Jimenez, W., Bibbiani, F., Morris, M. J., Dimitrova, T. D., Sherzai, A., Mouradian, M. M., & Chase, T. N. (2005) · Movement Disorders · doi:10.1002/mds.20370 · Cited by 160
Bar‐Am, O., Amit, T., & Youdim, M. B. H. (2003) · Neuroscience Letters · doi:10.1016/j.neulet.2003.10.067 · Cited by 157
Donepezil in the treatment of hallucinations and delusions in Parkinson’s disease
Fabbrini, G., Barbanti, P., Aurilia, C., Pauletti, C., Lenzi, G. L., & Meco, G. (2002) · Neurological Sciences · doi:10.1007/s100720200022 · Cited by 154
Wu, R., Chiueh, C. C., Pert, A., & Murphy, D. L. (1993) · European Journal of Pharmacology · doi:10.1016/0014-2999(93)90181-g · Cited by 152
Feng, B., Tse, H., Skifter, D. A., Morley, R., Jane, D. E., & Monaghan, D. T. (2004) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705644 · Cited by 147
Nicholson, S. L., & Brotchie, J. M. (2002) · European Journal of Neurology · doi:10.1046/j.1468-1331.9.s3.1.x · Cited by 146
Self-citationTahar, A. H., Grégoire, L., Dare, A., Bélanger, N., Meltzer, L. T., & Bédard, P. J. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2003.10.007 · Cited by 141
Costa, G., Abin-Carriquiry, J. A., & Dajas, F. (2001) · Brain Research · doi:10.1016/s0006-8993(00)03087-0 · Cited by 134
Kachroo, A., Orlando, L. R., Grandy, D. K., Chen, J., Young, A. B., & Schwarzschild, M. A. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3660-05.2005 · Cited by 134
Self-citationHenry, B., Fox, S. H., Crossman, A. R., & Brotchie, J. M. (2001) · Experimental Neurology · doi:10.1006/exnr.2001.7727 · Cited by 132
Self-citationPersistent Behavioral Sensitization to Chronic l-DOPA Requires A2AAdenosine Receptors
Fredduzzi, S., Moratalla, R., Monopoli, A., Cuéllar, B., Xu, K., Ongini, E., Impagnatiello, F., Schwarzschild, M. A., & Chen, J. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-03-01054.2002 · Cited by 128
Self-citationAkao, Y., Maruyama, W., Yi, H. L., Shamoto‐Nagai, M., Youdim, M. B. H., & Naoi, M. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00332-4 · Cited by 125
Perry, E. K., Smith, C. J., COURT, J. A., & Perry, R. H. (1990) · Journal of Neural Transmission - Parkinsons Disease and Dementia Section · doi:10.1007/bf02257646 · Cited by 124
Mori, A., & Shindou, T. (2003) · Neurology · doi:10.1212/01.wnl.0000095211.71092.a0 · Cited by 122
Calon, F., Birdi, S., Rajput, A. H., Hornykiewicz, O., Bédard, P. J., & Paolo, T. D. (2002) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/61.2.186 · Cited by 121
Self-citationCoccurello, R., Breysse, N., & Amalric, M. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300444 · Cited by 120
Calon, F., Morissette, M., Rajput, A. H., Hornykiewicz, O., Bédard, P. J., & Paolo, T. D. (2002) · Movement Disorders · doi:10.1002/mds.10343 · Cited by 110
Self-citationDeprenyl Protects Dopamine Neurons from the Neurotoxic Effect of 1‐Methyl‐4‐Phenylpyridinium Ion
Mytilineou, C., & Cohen, G. (1985) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1985.tb10556.x · Cited by 108
Iravani, M. M., Jackson, M. J., Kuoppamäki, M., Smith, L. A., & Jenner, P. G. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-27-09107.2003 · Cited by 106
Self-citationPramipexole protects against apoptotic cell death by non‐dopaminergic mechanisms
Gu, M., Irvani, M., Cooper, J. A. D., King, D., Jenner, P. G., & Schapira, A. H. V. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02804.x · Cited by 105
Self-citationLucas, G., Bonhomme, N., Deurwaerdère, P. D., Moal, M. L., & Spampinato, U. (1997) · Psychopharmacology · doi:10.1007/s002130050265 · Cited by 105
Self-citationFrechilla, D., Cobreros, A., Saldise, L., Moratalla, R., Insausti, R., Luquín, M. R., & R�o, J. D. (2001) · Synapse · Cited by 103
Maruyama, W., Takahashi, T., Youdim, M. B. H., & Naoi, M. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200038 · Cited by 101
Characterisation of UBP296: a novel, potent and selective kainate receptor antagonist
More, J. C. A., Nisticò, R., Dolman, N. P., Clarke, V. R. J., Alt, A. J., Ogden, A. M. L., Buelens, F. P., Troop, H. M., Kelland, E. E., Pilato, F., et al. (2004) · Neuropharmacology · doi:10.1016/j.neuropharm.2004.03.005 · Cited by 98
Self-citationBasal opioid receptor activity, neutral antagonists, and therapeutic opportunities
Sadée, W., Wang, D., & Bilsky, E. J. (2004) · Life Sciences · doi:10.1016/j.lfs.2004.10.024 · Cited by 95
Nash, J. E., Ravenscroft, P., McGuire, S., Crossman, A. R., Menniti, F. S., & Brotchie, J. M. (2004) · Experimental Neurology · doi:10.1016/j.expneurol.2004.05.004 · Cited by 94
Self-citationThe Molecular Basis of Opioid Receptor Function
Simonds, W. F. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-2-200 · Cited by 94
Werber, E. A., & Rabey, J. M. (2001) · Journal of Neural Transmission · doi:10.1007/s007020100008 · Cited by 89
Dopamine-receptor stimulation: biobehavioral and biochemical consequences
Calon, F., Tahar, A. H., Blanchet, P. J., Morissette, M., Grondin, R., Goulet, M., Doucet, J.-P., Robertson, G. S., Nestler, E. J., Paolo, T. D., et al. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00026-4 · Cited by 88
Self-citationPramipexole protects against MPTP toxicity in non‐human primates
Iravani, M., Haddon, C. O., Cooper, J., Jenner, P., & Schapira, A. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03625.x · Cited by 85
Self-citationFox, S. H., Moser, B., & Brotchie, J. M. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6792 · Cited by 82
Self-citationRascol, O., Fabre, N., Blin, O. J., Poulik, J. M., Sabatini, U., Sénard, J., Ané, M., Montastruc, J., & Rascol, A. (1994) · Movement Disorders · doi:10.1002/mds.870090410 · Cited by 82
Katzenschlager, R., Manson, A. J., Evans, A. H., Watt, H., & Lees, A. J. (2004) · PubMed · Cited by 71
5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease
Fox, S. H., & Brotchie, J. M. (2000) · Movement Disorders · doi:10.1002/1531-8257(200011)15:6<1064::aid-mds1002>3.0.co;2-c · Cited by 71
Self-citationQuetiapine Attenuates Levodopa-Induced Motor Complications in Rodent and Primate Parkinsonian Models
Oh, J. D., Bibbiani, F., & Chase, T. N. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.8009 · Cited by 71
Jeyarasasingam, G., Tompkins, L., & Quik, M. (2002) · Neuroscience · doi:10.1016/s0306-4522(01)00488-2 · Cited by 69
Disease modification in Parkinson's disease
Schapira, A. H. V. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00769-0 · Cited by 68
Self-citationNuman, S., Lundgren, K. H., Wright, D. E., Herman, J. P., & Seroogy, K. B. (1995) · Molecular Brain Research · doi:10.1016/0169-328x(95)00004-c · Cited by 67
Hunot, S., & Flavell, R. A. (2001) · Science · doi:10.1126/science.1060885 · Cited by 66
Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson’s disease
Jenner, P. G. (2004) · Neurology · doi:10.1212/wnl.63.7_suppl_2.s13 · Cited by 64
Self-citationO’Neill, M. J., Murray, T. K., Whalley, K., Ward, M., Hicks, C. A., Woodhouse, S., Osborne, D. J., & Skolnick, P. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2003.12.023 · Cited by 62
D1receptor blockade improves l -dopa–induced dyskinesia but worsens parkinsonism in MPTP monkeys
Grondin, R., Doan, V. D., Grégoire, L., et al. (1999) · Neurology · doi:10.1212/wnl.52.4.771 · Cited by 60
Fox, S. H., Silverdale, M., Kellett, M., Davies, R., Steiger, M. J., Fletcher, N. A., Crossman, A. R., & Brotchie, J. M. (2003) · Movement Disorders · doi:10.1002/mds.10693 · Cited by 58
Self-citationMirtazapine in l-Dopa-Induced Dyskinesias
Meco, G., Fabrizio, E., Rezze, S. D., Alessandri, A., & Pratesi, L. (2003) · Clinical Neuropharmacology · doi:10.1097/00002826-200307000-00005 · Cited by 55
Continuing trials of GDNF in Parkinson's disease
Barker, R. A. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70386-6 · Cited by 55
Caffeinated clues from epidemiology of Parkinson’s disease
Ascherio, A., & Chen, H. (2003) · Neurology · doi:10.1212/01.wnl.0000095213.86899.21 · Cited by 47
Neuroprotection in Parkinson's disease
Schapira, A. H. V. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70834-x · Cited by 46
Self-citationFox, S. H., & Brotchie, J. M. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00238-7 · Cited by 46
Self-citationEffect of MAO‐B Inhibitors on MPP+Toxicityin Vivo
Wu, R., CHEN, R., & Chiueh, C. C. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06191.x · Cited by 44
Counihan, T. J., Landwehrmeyer, G. B., Standaert, D. G., Kosinski, C. M., Scherzer, C. R., Daggett, L. P., Veli�elebi, G., Young, A. B., & Penney, J. B. (1998) · The Journal of Comparative Neurology · doi:10.1002/(sici)1096-9861(19980105)390:1<91::aid-cne8>3.0.co;2-l · Cited by 42
Short-term paroxetine treatment does not alter the motor response to levodopa in PD
Chung, K. A., Carlson, N. E., & Nutt, J. G. (2005) · Neurology · doi:10.1212/01.wnl.0000161841.41885.80 · Cited by 40
Hypersensitivity of cortical muscarinic receptors in Parkinson's disease demonstrated by PET
Asahina, M., Shinotoh, H., Hirayama, K., Suhara, T., Shishido, F., Inoue, O., & Tateno, Y. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1995.tb00443.x · Cited by 33
Clinical studies with transdermal rotigotine in early Parkinson’s disease
Poewe, W., & Luessi, F. (2005) · Neurology · doi:10.1212/wnl.65.2_suppl_1.s11 · Cited by 28
Principles of Treatment in Parkinson's Disease
(2005) · Elsevier eBooks · doi:10.1016/b978-0-7506-5428-9.x5001-x · Cited by 18
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Cited by
The 2.6 Angstrom Crystal Structure of a Human A 2A Adenosine Receptor Bound to an Antagonist
Jaakola, V.-P., Griffith, M. T., Hanson, M. A., Cherezov, V., Chien, E. Y. T., Lane, J. R., IJzerman, A. P., & Stevens, R. C. (2008) · Science · doi:10.1126/science.1164772 · Cited by 1,781
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
Mitochondria in the aetiology and pathogenesis of Parkinson's disease
Schapira, A. H. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(07)70327-7 · Cited by 883
Self-citationNicotinic receptors: allosteric transitions and therapeutic targets in the nervous system
Taly, A., Corringer, P.-J., Guedin, D., Lestage, P., & Changeux, J.-P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2927 · Cited by 703
Zhou, Y., Lu, M., Du, R.-H., Qiao, C., Jiang, C.-Y., Zhang, K.-Z., Ding, J.-H., & Hu, G. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0094-3 · Cited by 455
Metadata
- Authors
- Schapira, A. H. V., Bezard, E., Brotchie, J., Calon, F., Collingridge, G. L., Ferger, B., Hengerer, B., Hirsch, E., Jenner, P., Novère, N. L., Obeso, J. A., Schwarzschild, M. A., Spampinato, U., & Davidai, G.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-10
- Volume
- 5
- Issue
- 10
- Pages
- 845-854
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2004536195
- Cited by
- 298
- References
- 115
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.